FDA Feels Heat Alongside J&J As House Oversight Investigates OTC Recall
This article was originally published in The Tan Sheet
Executive Summary
FDA finds itself under congressional scrutiny alongside Johnson & Johnson even as the agency investigates and weighs possible enforcement against J&J following the firm's third OTC recall in eight months
You may also be interested in...
FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare